The news directly pertains to Rani Therapeutics Hldgs as B of A Securities has lowered its price target for the company. However, the Buy rating is maintained, indicating that the analyst still sees potential in the stock. This could have a neutral impact on the stock's price in the short term as the lowered price target might deter some investors, but the maintained Buy rating could also attract others.